Rational design and synthesis of novel diphenyl ether derivatives as antitubercular agents

References

• Global Tuberculosis ReportGenevaWorld Health Organization2014
   Google Scholar
• GreenKDGarneau-TsodikovaSResistance in tuberculosis: what do we know and where can we go?Front Microbiol2013420823888158
   PubMed Web of Science ®Google Scholar
• RiccardiGPascaMRTrends in discovery of new drugs for tuberculosis therapyJ Antibiot20146765565925095807
   PubMed Web of Science ®Google Scholar
• PayneDJWarrenPVHolmesDJJiYLonsdaleJTBacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discoveryDrug Discov Today2001653754411369293
   PubMed Web of Science ®Google Scholar
• LamichhaneGNovel targets in M. tuberculosis: search for new drugsTrends Mol Med200117253321071272
   PubMedGoogle Scholar
• SullivanTJTruglioJJBoyneMEHigh affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosisACS Chem Biol20061435317163639
   PubMed Web of Science ®Google Scholar
• HeathRJYuYTShapiroMAOlsonERockCOBroad spectrum antimicrobial biocides target the FabI component of fatty acid synthesisJ Biol Chem199827330316303209804793
   PubMed Web of Science ®Google Scholar
• TipparajuSKMulhearnDCYangSDesign and synthesis of novel aryl ether inhibitors of the Bacillus anthracis enoyl-ACP reductaseChemMedChem2008312601268
   Web of Science ®Google Scholar
• TipparajuSKJoyasawalSForresterSDesign and synthesis of 2-pyridones as novel inhibitors of the Bacillus anthracis enoyl–ACP reductaseBioorg Med Chem Lett2008183565356918499454
   PubMed Web of Science ®Google Scholar
• TakahataSIidaMOsakiYAG205, a novel agent directed against FabK of Streptococcus pneumoniaeAntimicrob Agents Chemother2006502869287116870790
   PubMed Web of Science ®Google Scholar
• TakahataSIidaMYoshidaTDiscovery of 4-Pyridone derivatives as specific inhibitors of enoyl-acyl carrier protein reductase (FabI) with antibacterial activity against Staphylococcus aureusJ Antibiot20076012312817420562
   PubMed Web of Science ®Google Scholar
• KitagawaHOzawaTTakahataSIidaMSaitoJYamadaMPhenyl imidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabKJ Med Chem2007504710472017713898
   PubMed Web of Science ®Google Scholar
• McLeodRMuenchSPRaffertyJBTriclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab IInt J Parasitol20013110911311239932
   PubMed Web of Science ®Google Scholar
• WangLQFalanyCNJamesMOTriclosan as a substrate and inhibitor of 3′-phosphoadenosine-5′-phosphosulfate-sulfotransferase and UDP-glucuronosyl transferase in human liver fractionsDrug Metab Dispos2004321162116915269185
   PubMed Web of Science ®Google Scholar
• ThomasCAKarSSBairyIBhatVGShenoyVPShenoyGGSynthesis and evaluation of antitubercular activity of novel diphenyl ether derivativesInd Glob J Pharm Sci201551925
   Google Scholar
• ThomasCAKarSSBairyIBhatVGShenoyVPShenoyGGDesign, synthesis and evaluation of antitubercular activity of triclosan analoguesArabian J Chem2015 (accepted). Available from: http://dx.doi.org/10.1016/j.arabjc.2015.09.003
   Google Scholar
• SivaramanSSullivanTJJohnsonFInhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analoguesJ Med Chem20044750951814736233
   PubMed Web of Science ®Google Scholar
• EvansDAKatzJLWestTRSynthesis of diaryl ethers through the copper-promoted arylation of phenols with arylboronic acids. An expedient synthesis of thyroxineTetrahedron Lett19983929372940
   Web of Science ®Google Scholar
• Abdel HafezOMAhmedMKHaggagEESynthesis of some potentially bioactive compounds from visnaginoneMolecules20016396405
   Web of Science ®Google Scholar
• EllisJEDavisEMBrowerPLA novel and practical method for hydrocyanation of chalconesOrg Pro Res Dev19971250252
   Web of Science ®Google Scholar
• KatritzkyARPilarskiBUrogdiLEfficient conversion of nitriles to amides with basic hydrogen peroxide in dimethyl sulfoxideSynthesis198912949952
   Google Scholar
• GillmoreALauretCRobertsSMA route to the structure proposed for puetuberosanol and approaches to the natural products marshrin and phebalosinTetrahedron20035943634375
   Web of Science ®Google Scholar
• LeonardBCoronelJSiednerMInter- and intra-assay reproducibility of microplate alamar blue assay results for isoniazid, rifampicin, ethambutol, streptomycin, ciprofloxacin, and capreomycin drug susceptibility testing of Mycobacterium tuberculosisJ Clin Microbiol2008463526352918701659
   PubMed Web of Science ®Google Scholar
• CollinsLFranzblauSGMicroplate alamar blue assay versus BACTEC 460 System for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium aviumAntimicrob Agents Chemother199741100410099145860
   PubMed Web of Science ®Google Scholar
• MorganDMLTetrazolium (MTT) assay methods in molecular biology for cellular viability and activityPolyamine Protocols199879179182
   Google Scholar
• SinghMSasiPRaiGGuptaVHAmarapurkarDWangikarPPStudies on toxicity of antitubercular drugs namely isoniazid, rifampicin, and pyrazinamide in an in vitro model of HepG2 cell lineMed Chem Res20112016111615
   Web of Science ®Google Scholar
• SundermannVMKnasmullerSWuXJDarroudiFKassieFUse of a human- derived liver cell line for the detection of cytoprotective, antigenotoxic and cogenotoxic agentsToxicology200419832934015138059
   PubMed Web of Science ®Google Scholar
• LipinskiCADrug-like properties and the causes of poor solubility and permeabilityJ Pharmacol Toxicol Methods20004423524911274893
   PubMed Web of Science ®Google Scholar
• Suite 2010: Maestro, version 9.2Schrödinger, LLCNew York, NY2010
   Google Scholar
• KuoMRMorbidoniHRAllandDTargeting tuberculosis and malaria through inhibition of enoyl reductase: compound activity and structural dataJ Biol Chem2003278208512085912606558
   PubMed Web of Science ®Google Scholar
• LombardoFShalaevaMYTupperKAGaoFAbrahamMHElogPoct: a tool for lipophilicity determination in drug discoveryJ Med Chem2000432922292810956200
   PubMed Web of Science ®Google Scholar
• WiczlingPMarkuszewskiMJKaliszanRDetermination of pKa by pH gradient reversed-phase HPLCAnal Chem2004763069307715167784
   PubMed Web of Science ®Google Scholar
• KaliszanRHaberPBaczekTSilukDValkoKLipophilicity and pKa estimates from gradient high-performance liquid chromatographyJ Chromatogr A200296511712712236521
   PubMed Web of Science ®Google Scholar
• HollósyFValkóKHerseyANunhuckSKériGBevanCEstimation of volume of distribution in humans from high throughput HPLC-based measurements of human serum albumin binding and immobilized artificial membrane partitioningJ Med Chem2006496958697117125249
   PubMed Web of Science ®Google Scholar
• RowleyMKulagowskiJJWattAPEffect of plasma protein binding on in vivo activity and brain penetration of Glycine/NMDA receptor antagonistsJ Med Chem199740405340689406596
   PubMed Web of Science ®Google Scholar
• RotroffDMWetmoreBADixDJIncorporating human dosimetry and exposure into high-throughput in vitro toxicity screeningToxicol Sci2010117234835820639261
   PubMed Web of Science ®Google Scholar
• HillJRIn vitro drug metabolism using liver microsomesCurr Prot Pharmacol20037.8.17.8.11
   Google Scholar
• Mammalian Liver Microsomes Guidelines for Use. TF000017 Rev 1.0, 1, BD Biosciences Available from: http://www.industrycortex.com/datasheets/profile/759758262/manual-tf000017-rev-1.0-mammalian-liver-microsomes-guidelines-forAccessed April 12, 2014
   Google Scholar